Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma

Phase 2 Completed 39 enrolled UNC Lineberger Comprehensive Cancer Center Fogarty International Center of the National Institute of Health · collab National Cancer Institute (NCI) · collab National Institutes of Health (NIH) · collab

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to establish the safety of rituximab plus cyclophosphamide, doxorubicin, vincristine,prednisone (R-CHOP) in HIV-infected and HIV-uninfected diffuse large B-cell lymphoma (DLBCL) patients in Malawi.

Timeline

Start: 2016-03
Primary completion: 2021-07-22
Completion: 2022-07-22

Publications

Kimani S, Painschab MS, Kaimila B, Kasonkanji E, Zuze T, Tomoka T, Mulenga M, Nyasosela R, Chikasema M, Mtangwanika A, Chawinga M, Mhango W, Nicholas S, Chimzimu F, Kampani C, Krysiak R, Lilly A, Randall C, Seguin R, Westmoreland KD, Montgomery ND, Fedoriw Y, Gopal S. Safety and efficacy of rituximab in patients with diffuse large B-cell lymphoma in Malawi: a prospective, single-arm, non-randomised phase 1/2 clinical trial. Lancet Glob Health. 2021 Jul;9(7):e1008-e1016. doi: 10.1016/S2214-109X(21)00181-9. Epub 2021 May 19.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cyclophosphamide	Other / unclassified	750 mg/m2	Intravenous
Subject	Doxorubicin	Other / unclassified	50 mg/m2	Intravenous
Subject	Prednisone	Other / unclassified	100 mg	Oral
Subject	Rituximab	Monoclonal antibody	375 mg/m2	Intravenous
Subject	Vincristine	Small molecule	1.4 mg/m2	Intravenous

Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma

Summary

Timeline

Publications

Drugs

Indications